Search

Your search keyword '"Valteau-Couanet, D."' showing total 79 results

Search Constraints

Start Over You searched for: Author "Valteau-Couanet, D." Remove constraint Author: "Valteau-Couanet, D." Search Limiters Full Text Remove constraint Search Limiters: Full Text
79 results on '"Valteau-Couanet, D."'

Search Results

1. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

3. Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials

4. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study

5. Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial

7. Diffuse intrinsic pontine gliomas (DIPG) at recurrence : is there a window to test new therapies in some patients?

8. LBA64 - Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial

9. RISK FACTORS WITHIN THE EUROPEAN HIGH RISK NEUROBLASTOMA HR-NBL1/SIOPEN TRIAL

11. NEUROPSYCHOLOGY

12. CLINICAL TRIALS

13. MEDULLOBLASTOMA

17. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

18. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.

19. p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma.

20. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study

21. Thoracoscopy for Pediatric Thoracic Neurogenic Tumors-A European Multi-Center Study.

22. Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?

23. Long-term hospitalisations in survivors of paediatric solid tumours in France.

24. Health care expenditures among long-term survivors of pediatric solid tumors: Results from the French Childhood Cancer Survivor Study (FCCSS) and the French network of cancer registries (FRANCIM).

25. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.

26. Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma.

27. Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.

28. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).

29. [Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives].

30. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

31. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

32. IL-2 antibodies in type 1 diabetes and during IL-2 therapy.

33. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.

34. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.

35. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.

36. High-dose thiotepa-related neurotoxicity and the role of tramadol in children.

37. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD 2 antibody ch14.18/CHO.

38. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.

39. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.

40. Relationships between Regional Radiation Doses and Cognitive Decline in Children Treated with Cranio-Spinal Irradiation for Posterior Fossa Tumors.

41. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.

42. Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey.

43. Educational and occupational outcomes of childhood cancer survivors 30 years after diagnosis: a French cohort study.

44. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.

45. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.

46. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.

47. Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients.

48. GALNT9 gene expression is a prognostic marker in neuroblastoma patients.

49. Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival.

50. ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Catalog

Books, media, physical & digital resources